A method for preparing chiral aza-quinoline compounds
Through the combination of enzyme hydrolysis and condensation reaction, chiral S-configured oxapropionylcyclobutylamine is directly prepared, solving the problems of low efficiency and high cost of supercritical fluid chromatography in the prior art, and achieving high efficiency and large-scale Production and high purity preparation.
Patent Information
- Application Number
- CN202411076604.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-07
AI Technical Summary
The existing preparation methods for S-configured oxapropionylcyclobutylamine are not suitable for large-scale production and require supercritical fluid chromatography to resolve, which is inefficient and costly, and cannot directly obtain chiral products.
Using a combination of enzymatic hydrolysis reaction and condensation reaction, the enzyme hydrolysis of compound III is carried out in the presence of ester hydrolase to obtain compound II, and the condensation reaction is carried out with 3-oxetamide hydrochloride in the presence of condensation reagent. , the chiral S configuration oxapropionylcyclobutylamine was obtained directly, and the efficiency and cost bottleneck of supercritical fluid chromatography was broken through using enzyme separation method.
The preparation of S-configured oxapropionylcyclobutylamine with simple operation, high yield and suitable for large-scale production is achieved, and chiral products are directly obtained, which improves the overall yield and reduces costs, and does not decrease chiral purity.
Smart Images

Figure SMS_1 
Figure SMS_6 
Figure SMS_7
Abstract
Description
Technical Field
[0001] The invention relates to the field of drug synthesis, and in particular to a method for preparing S-configuration oxapropionylcyclobutane amine. Background Art
[0002] Histone-lysine N-methyltransferase (EZH2) plays an important role in development and adult tissue homeostasis and is closely related to a variety of diseases. EZH2, SUZ12 and EED are overexpressed in many cancers, including but not limited to breast cancer, prostate cancer and hepatocellular carcinoma. EZH2 activating mutations have been found in patients with DLBCL (diffuse large B-cell lymphoma), FL (follicular lymphoma), melanoma and parathyroid carcinoma (EZH2 activating mutations lead to increased H3K27me3). Inhibition of PRC2 methyltransferase activity by compounds competing with the cofactor SAM or directly binding to EED in DLBCL reverses the high H3K27me3 state, reactivates the expression of target genes and inhibits tumor growth / proliferation. In addition, EZH2 inhibitors can release the suppression of Th1 chemokines in tumor cells and enhance T cell infiltration in ovarian and colorectal cancers.
[0003] (S)2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetane-3-yl)propanamide (referred to as S-configuration oxetaneylcyclobutaneamide in this application) as shown in formula (I) is an EZH2 inhibitor and has broad prospects in the treatment of breast cancer, prostate cancer and hepatocellular carcinoma.
[0004]
[0005] Chinese patent CN114746414A discloses a method for preparing S-configuration oxapropionylcyclobutylamine, but the method uses supercritical fluid chromatography (SFC) separation and is only suitable for laboratory-level preparation and not for large-scale production.
[0006] Therefore, there is an urgent need for a preparation method for S-configuration oxapropionylcyclobutylamine which is simple to operate, has a high yield and is suitable for large-scale production. Summary of the invention
[0007] In order to solve the above problems, the present invention provides a method for preparing S-configuration oxapropionylcyclobutylamine which is simple to operate, has high yield and is suitable for large-scale production.
[0008] In the first aspect of the present invention, a method for preparing S-configuration oxapropionylcyclobutylamine is provided, comprising the following steps:
[0009] (i) In the presence of an esterase, compound III is subjected to an enzymatic hydrolysis reaction to obtain compound II: ;
[0010] Wherein, the esterase is selected from the following group: Lipase AS, Lipase AYS, Lipase AK, Lipase PS (all purchased from Wako Pure Chemical Industries, Ltd.), Palatase 20000 L, Novozym 435, Lipozyme TL IM (all purchased from Novozymes), 503030-V5 (purchased from Alexin), or a combination thereof;
[0011] (ii) In the presence of a condensation agent, the compound of formula II and 3-oxetane hydrochloride undergo a condensation reaction to obtain compound I, i.e., S-configuration oxapropionyl cyclobutane amine: .
[0012] In a preferred embodiment, in the step (i), the esterase is selected from the group consisting of: Palatase 20000 L, Novozym 435, 503030-V5, or a combination thereof.
[0013] In another preferred embodiment, the enzyme is 503030-V5 (a commercially available product, the specific sequence of which is recorded in CN113502281B).
[0014] In a preferred example, in the step (i), the mass ratio of the compound III to the esterase is 1:(0.1-3).
[0015] In another preferred embodiment, in the step (i), the mass ratio of the compound III to the esterase is 1:(0.5-2.5), preferably 1:(1-2).
[0016] In a preferred embodiment, in the step (i), the temperature of the enzymatic hydrolysis reaction is 30-50°C.
[0017] In another preferred embodiment, in the step (i), the temperature of the enzymatic hydrolysis reaction is 32-45°C, preferably 35-40°C.
[0018] In another preferred embodiment, in the step (i), the enzymatic hydrolysis reaction time is 2-28 h, preferably 10-30 h, and more preferably 18-22 h.
[0019] In another preferred embodiment, in the step (i), the pH range of the enzymatic hydrolysis reaction is 6.0-9.0, preferably 7.0-9.0, and more preferably 7.5-8.0.
[0020] In another preferred embodiment, in the step (i), the enzymatic hydrolysis reaction is carried out in the presence of a buffer solution, and the buffer solution is a phosphate buffer solution.
[0021] In another preferred embodiment, in the step (i), the buffer is potassium dihydrogen phosphate / dipotassium hydrogen phosphate buffer.
[0022] In another preferred embodiment, the enzymatic hydrolysis reaction is carried out in the presence of solvent A, and the solvent A is dimethyl sulfoxide.
[0023] In another preferred embodiment, the step (i) further comprises: post-treating the liquid obtained after enzymatic hydrolysis to obtain the compound II.
[0024] In another preferred embodiment, in the step (i), the post-treatment comprises: adding sodium chloride to the feed solution, adjusting the pH to acidic, adding diatomaceous earth and stirring, centrifuging to obtain filter cake a and centrifugal liquid, and adjusting the pH of the centrifugal liquid to weak alkaline to obtain a mother liquor.
[0025] In another preferred embodiment, in the step (i), the post-treatment further comprises: adding isopropyl acetate to the filter cake obtained in the above step for slurrying, thereby obtaining a slurry filtrate, and combining it with the mother liquor to form a feed liquid containing the compound II.
[0026] In another preferred embodiment, in the step (i), the post-treatment further comprises: adjusting the pH of the solution containing the compound II obtained in the above step to alkaline, and collecting the aqueous phase after standing and separating the liquid.
[0027] In another preferred embodiment, in the step (i), the post-treatment further comprises: adjusting the pH of the aqueous phase to acidic, filtering, and obtaining a filter cake b.
[0028] In another preferred embodiment, the method further comprises the steps of: washing the filter cake b with an aqueous potassium dihydrogen phosphate solution, filtering the solid phase, and obtaining a compound of formula II.
[0029] In a preferred embodiment, the method further comprises the following step (i-2): recovering the R-configuration compound III in the feed solution in step (i), i.e., compound R-III; subjecting compound R-III to a racemization reaction in the presence of DBU to obtain compound III; .
[0030] In another preferred embodiment, the method further comprises the following step (i-3): Compound III obtained in step (i-2) is subjected to the enzymatic hydrolysis reaction of step (i) to obtain Compound II.
[0031] In another preferred embodiment, the method further includes the following steps (i-2): using 2-methyltetrahydrofuran to recover the R-configuration compound III in the feed solution in step (i), i.e., compound R-III; after adding ethanol, in the presence of DBU, compound R-III undergoes a racemization reaction to obtain compound III; compound III undergoes the enzymatic hydrolysis reaction of step (i) to obtain compound II.
[0032] In another preferred embodiment, in the step (i-2), the molar ratio of the R configuration to the S configuration in the compound III obtained by the racemization reaction is 1: (0.99~1.01).
[0033] In another preferred embodiment, in the step (i-2), the molar ratio of DBU to compound R-III in the feed solution is 1: (0.1-3), preferably 1: (0.5-2), and more preferably 1: (0.8-1.2).
[0034] In another preferred embodiment, the racemization reaction temperature is 10-45°C, preferably 15-35°C, and more preferably 20-25°C.
[0035] In another preferred embodiment, the racemization reaction time is 4 to 20 h, preferably 4 to 15 h, and more preferably 6 to 10 h.
[0036] In another preferred embodiment, the method further comprises the following step (i-4): combining the compound II obtained in step (i) and step (i-3) and purifying them to obtain compound II.
[0037] In another preferred embodiment, the step (i-2) further comprises: post-treating the liquid obtained after racemization to obtain the compound III.
[0038] In another preferred embodiment, in the step (i-2), the post-treatment comprises:
[0039] a. The racemized feed solution was quenched with ammonium chloride solution to obtain a reaction solution;
[0040] b. The reaction solution was allowed to stand to obtain an upper organic phase and a lower aqueous phase, and the lower aqueous phase was extracted with isopropyl acetate to obtain an extract, and the upper organic phase and the extract were combined to obtain an organic phase;
[0041] c. The organic phase obtained in step b was washed with an aqueous sodium chloride solution, concentrated, and n-heptane was added dropwise and filtered to obtain compound III.
[0042] In a preferred embodiment, in the step (ii), the molar ratio of the compound of formula II to 3-oxetaneamine hydrochloride is 1: (0.1-4).
[0043] In another preferred embodiment, in the step (ii), the molar ratio of the compound of formula II to 3-oxetaneamine hydrochloride is 1: (0.5-3), preferably 1: (1-2).
[0044] In a preferred embodiment, in the step (ii), the condensation reagent is selected from the following group: T3P, PyBOP, TCFH, or a combination thereof.
[0045] In another preferred embodiment, in the step (ii), the condensation reagent is T3P.
[0046] In another preferred embodiment, the condensation reagent is dissolved in reagent C, and the reagent C is ethyl acetate.
[0047] In another preferred embodiment, the condensation reagent is 40-60 wt% of T3P in ethyl acetate solution.
[0048] In another preferred embodiment, the condensation reagent is 45-55 wt% of T3P in ethyl acetate solution.
[0049] In another preferred embodiment, the molar ratio of the compound II to the condensation reagent is 1: (0.1-4), preferably 1: (1-3), and more preferably 1: (1-2).
[0050] In a preferred embodiment, in the step (ii), the condensation reaction is carried out in the presence of solvent B, and the solvent B is selected from the following group: dichloromethane, acetonitrile, or a combination thereof.
[0051] In a preferred embodiment, in the step (ii), the condensation reaction is carried out in the presence of a base B, and the base B is selected from the following group: N,N-diisopropylethylamine, triethylamine, methylimidazole, or a combination thereof.
[0052] In another preferred embodiment, in the step (ii), the molar ratio of compound II to base B is 1: (2-20), preferably 1: (5-15), and more preferably 1: (8-12).
[0053] In another preferred embodiment, the temperature of the condensation reaction is -10~10°C, preferably -8~8°C, and more preferably -5~5°C.
[0054] In another preferred embodiment, the condensation reaction time is 5-25 h, preferably 8-20 h, and more preferably 12-16 h.
[0055] In a preferred embodiment, the compound III is prepared by the following steps (i'): Compound V and compound IV undergo a substitution reaction to obtain compound III: .
[0056] In another preferred embodiment, the molar ratio of compound IV to compound V is 1: (0.2-3), preferably 1: (0.5-2), and more preferably 1: (0.8-1.5).
[0057] In another preferred embodiment, the reaction temperature of step (i') is 65-95°C, preferably 70-90°C, more preferably 75-85°C.
[0058] In another preferred embodiment, the reaction time of step (i') is 50-90 h, preferably 50-80 h, more preferably 55-70 h.
[0059] In another preferred embodiment, the step (i') is carried out in the presence of a base A.
[0060] In another preferred embodiment, in the step (i'), the base A is selected from the following group: N,N-diisopropylethylamine, potassium phosphate, potassium carbonate, cesium carbonate, or a combination thereof.
[0061] In another preferred embodiment, in the step (i'), the molar ratio of compound IV to base A is 1: (2-12), preferably 1: (4-10), and more preferably 1: (5-8).
[0062] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here.
[0063] The main advantages of the present invention are:
[0064] 1. The present invention provides a chiral preparation method of S-configuration oxapropionylcyclobutylamine. The prior art does not provide a direct preparation method for the compound, so the chiral product can only be obtained by first preparing a racemic product and then resolving the product by supercritical fluid chromatography (SFC), which cannot be used for industrial production. The enzymatic resolution method used in the present invention can directly obtain the chiral product, breaking through the bottleneck of low efficiency, high cost and inability to large-scale production of supercritical fluid chromatography resolution, and has extremely high creativity.
[0065] 2. The present invention also provides a preparation method for improving the overall yield and reducing the cost. After the ester hydrolysis reaction, the raw material of another chiral configuration (i.e., compound R-III) in the waste is racemized to obtain a raw material with a near 1:1 ratio of R configuration to S configuration (i.e., compound III), which can be enzymatically hydrolyzed again to obtain compound II again.
[0066] 3. The present invention also provides a method for preparing high-purity chiral oxapropionylcyclobutylamine. In the presence of a specific condensation reagent, the chiral carboxylic acid obtained by ester hydrolysis can undergo a condensation reaction with oxocyclobutylamine to directly obtain the chiral oxapropionylcyclobutylamine without reducing its chiral purity. DETAILED DESCRIPTION
[0067] After long and in-depth research and extensive screening, the inventors have developed for the first time a method for preparing S-configuration oxapropionylcyclobutaneamine that is simple to operate, has a high yield, and is suitable for large-scale production.
[0068] the term
[0069] As used herein, "ee" is an abbreviation for enantiomeric excess, which refers to the enantiomeric excess, which is defined as the percentage of the excess of one isomer a over the other isomer b in a mixture of enantiomers.
[0070] Abbreviations
[0071] T3P: 1-propylphosphonic anhydride
[0072] MYTsA: N-methylethynyl-p-toluenesulfonamide
[0073] TCFH: Tetramethylchlorouronium hexafluorophosphate
[0074] DIPEA: N,N-diisopropylethylamine
[0075] TEA: triethylamine
[0076] NMI: Methylimidazole
[0077] DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene
[0078] DCM: dichloromethane
[0079] ACN: Acetonitrile
[0080] RRT: relative retention time
[0081] LiHMDS: Lithium bis(trimethylsilyl)amide
[0082] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually carried out under normal conditions or under the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0083] Example 1 Preparation of Compound III (Step i')
[0084]
[0085] Table 1. Step i' material table
[0086]
[0087] reaction:
[0088] 1. Add 14.7 g of compound IV and 200 mL of ethanol into reaction bottle 1.
[0089] 2. Control the temperature at 15 ~ 25℃ and add 53.3 g of N,N - diisopropylethylamine (DIPEA) and 20.0 g of compound V.
[0090] 3. The reaction system was kept at 75 ~ 85 ° C for 60 h (sampling and testing until the purity of compound V is ≤4.0 area%) to obtain compound III.
[0091] Post-processing:
[0092] 1. Cool down, add 200 mL of isopropyl acetate and 200 mL of purified water, stir and separate the liquids, and collect the upper organic phase.
[0093] 2. Extract the aqueous phase with 100 mL of isopropyl acetate.
[0094] 3. Combine the organic phases, control the temperature at ≤ 45°C, and concentrate to 160 ~ 200 mL.
[0095] 4. Adjust the temperature to 15 ~ 25℃, add 500 mL of n-heptane to the concentrated system, and keep warm for crystallization until the external standard content of compound III in the mother liquor is ≤ 0.30 wt%.
[0096] 5. Filter and rinse the filter cake with 40 mL of n-heptane; dry at T ≤ 50°C to obtain 24.10 g of compound III with a purity of 96.41%, a content of 96.19%, and a yield of 73.3%.
[0097] Example 2 Screening of esterase in the preparation of compound II
[0098] 2.1 Screening of esterase types
[0099]
[0100] 10 wt% enzyme (based on the mass of compound III) and compound III dissolved in 20 volumes of DMSO were added to the reactor, and a buffer solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate was added. The reaction system was placed on a shaker for reaction. The reaction results are shown below:
[0101]
[0102] The experimental results showed that both Novozym 435 and 503030-V5 had excellent ester hydrolysis effects, among which 503030-V5 had the best effect.
[0103] 2.2 Screening of optimal reaction conditions for ester hydrolase
[0104] The reaction temperature, reaction time and system pH of the optimal esterase 503030-V5 were further screened, and the other steps were the same as those in the above 2.1.
[0105]
[0106] Table 2. Screening of the optimal reaction conditions for ester hydrolase
[0107]
[0108] The screening results showed that the hydrolysis effect of 503030-V5 was best when pH ≈ 7.5, reaction temperature was 35-40℃, and reaction time was 20 h.
[0109] Example 3 Preparation of Compound II (Step i)
[0110]
[0111] Table 3. Step i material table
[0112]
[0113] reaction:
[0114] 1. Add 16000 g of K2HPO4-KH2PO4 (pH=7.4, 0.2M) buffered saline solution into the reaction flask.
[0115] 2. Control the temperature at 20-40℃ and add 294g hydrolase powder into the system.
[0116] 3. Dissolve compound III completely in 4000 mL of DMSO.
[0117] 4. Control the temperature at 20-40℃ and add the DMSO solution of compound III into the system.
[0118] 5. Heat the system to 35-40°C and stir overnight to obtain compound II.
[0119] Post-processing:
[0120] 1. After the reaction is completed, cool down to 20-30℃, add 2000 g of sodium chloride solid to the system, and stir for 0.5-1h. 2. Control the temperature at 20-30℃, use 3M hydrochloric acid solution to adjust the pH to 2.5-3.0, and stir for 2-4h.
[0121] 3. Add 300 g of diatomaceous earth to the system and continue stirring for 0.5-1 h.
[0122] 4. Centrifuge the system, and the filter cake is ready for treatment. Use sodium hydroxide solution to adjust the pH of the centrifuge to 7.5-8.0 to obtain the mother liquor.
[0123] 5. Slurry the filter cake with isopropyl acetate three times, 8 L each time, collect and combine the filtrates.
[0124] 6. Control the temperature at 20-30℃, combine the mother liquor and pulping filtrate, adjust the pH of the water phase to 9.3-9.7 and stir for 1-2 hours.
[0125] 7. Keep the temperature at 30-40℃ and let the system stand for separation. Collect the aqueous phase and the isopropyl acetate organic phase containing R-configuration compound III (compound R-III) for the subsequent racemization step (temporarily store for later use).
[0126] 8. Control the temperature at 20-30℃, adjust the pH of the water phase to 4.0-4.5, precipitate the product and filter.
[0127] 9. Control the temperature at 20-30℃ and slurry the product with 3 L of 1% potassium dihydrogen phosphate aqueous solution for 4-6 hours.
[0128] 10. Filter, collect the filter cake, and dry to obtain compound II.
[0129] Example 4 Condition Screening for the Racemization Reaction of R-Configuration Compound III (Compound R-III)
[0130]
[0131] Reaction steps:
[0132] 1. Control the temperature to ≤45°C, and concentrate the isopropyl acetate organic phase containing R-III obtained in Example 3 to 3-4 times the volume.
[0133] 2. Use 2-methyltetrahydrofuran to replace isopropyl acetate three times, 10 times the volume each time, and finally concentrate to 3-4 times the volume.
[0134] 3. Add 2-methyltetrahydrofuran to 10 times the volume, then add 1 times the volume of anhydrous ethanol and stir evenly.
[0135] 4. Control the temperature at 20-25°C and add 1 eq of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) dropwise.
[0136] 5. Control the temperature at 20-25°C and stir for 16-20 h to obtain compound III.
[0137] Table 4. ee values of the reaction products (Compound III) under different bases, reaction temperatures and reaction times
[0138]
[0139] Note: 1. ee value before racemization: -55.3%
[0140] 2. When the ee value is 0, racemization is complete
[0141] The experimental results show:
[0142] 1. Triethylamine, sodium carbonate and potassium carbonate cannot be racemized at any temperature.
[0143] 2. LiHMDS can almost completely racemize the raw material at -20oC in 17 hours.
[0144] 3. Cesium carbonate can be almost completely racemized after reacting at 0℃ for 24 hours. 4. DBU can be almost completely racemized after reacting at 25℃ for 8 hours.
[0145] In summary, considering the low cost of DBU, the suitable reaction temperature (25 °C), and the short reaction time (8 h), DBU is preferred for racemization reaction.
[0146] Example 5 Racemization reaction of R-configuration compound III (compound R-III)
[0147]
[0148] Reaction steps (operation process is the same as Example 4):
[0149] 1. Control the temperature to ≤45°C, and concentrate the isopropyl acetate organic phase containing R-III obtained in Example 3 to 3-4 times the volume.
[0150] 2. Use 2-methyltetrahydrofuran to replace isopropyl acetate three times, 10 times the volume each time, and finally concentrate to 3-4 times the volume.
[0151] 3. Add 2-methyltetrahydrofuran to 10 times the volume, then add 1 times the volume of anhydrous ethanol and stir evenly.
[0152] 4. Control the temperature at 20-25°C and add 1 eq of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) dropwise.
[0153] 5. Control the temperature at 20-25°C and stir for 16-20 h to obtain compound III.
[0154] Post-processing:
[0155] 1. Control the temperature at 0-10℃ and add the reaction system dropwise into 6L of saturated ammonium chloride solution to quench.
[0156] 2. The system was allowed to stand for separation to obtain an upper organic phase and a lower aqueous phase. The lower aqueous phase was back-extracted with 1 L of isopropyl acetate to obtain an extract. The upper organic phase and the extract were combined to obtain an organic phase.
[0157] 3. Wash the organic phase with 2 L of saturated sodium chloride aqueous solution.
[0158] 4. Concentrate the organic phase to 400-600 mL, then add 4 L of n-heptane. After the addition is complete, stir for 3-5 hours and filter.
[0159] 5. Compound III was obtained in an amount of 50 g with a purity of 98.57%, a content of 98.60%, an ee value of 97.54%, and a yield of 27%.
[0160] The compound III obtained after racemization is subjected to the enzymatic hydrolysis reaction of step (i) to obtain compound II, which is used for the next reaction.
[0161] Example 6 Screening of condensing agents and bases in the preparation of compound I
[0162]
[0163] 6.1 Screening of condensing agents used in the preparation of compound I
[0164] Table 6. Screening of condensing agents used in the preparation of compound I
[0165]
[0166] *50% T3P in this application refers to a 50 wt% T3P solution in ethyl acetate.
[0167] Reaction steps:
[0168] 1. Add 1100 mL of dichloromethane and 110 g of compound II (ee value 97.54%) into the reactor at room temperature, stir and cool down.
[0169] 2. Cool down to -5~5℃, add 3-oxetane hydrochloride (41.0g, 1.5 eq) to the reaction bottle, and then drop N,N-diisopropylethylamine (322.4g, 10.0 eq) and 50 wt% 1-propylphosphoric anhydride ethyl acetate solution (476.4g, 1.5 eq) in sequence.
[0170] 3. Control the temperature at -5~5℃ and react for 12~16 hours (take samples until the remaining compound II is ≤0.5%) to obtain compound I.
[0171] The experimental results show:
[0172] It can be seen from Experiment 1 that when Zhao's catalyst is used as a condensation agent, the reaction does not occur and no product (Compound I) is generated.
[0173] It can be seen from Experiments 2 and 3 that when TCFH is used as a condensation agent, the conversion rate of the reaction is low.
[0174] It can be seen from Experiments 3 and 4 that when PyBOP and T3P are used as condensation agents, the conversion rate of the reaction is better, and the chiral purity is higher when T3P is used as the condensation agent (ee value > 95%).
[0175] In summary, T3P was selected as the most preferred condensation agent in this reaction process.
[0176] 6.2 Screening of bases used in the preparation of compound I
[0177] Table 7. Screening of bases used in the preparation of compound I
[0178]
[0179] The remaining reaction steps are the same as in 6.1.
[0180] The experimental results show:
[0181] From Experiments 1 to 3, it can be seen that the ee value of compound I is higher when DIPEA is used as a base compared with TEA as a base.
[0182] It can be seen from Experiments 4 and 5 that the more base is used, the higher the conversion rate of the reaction is, and the increase in the amount of base does not affect the ee value of the product (Compound I).
[0183] Example 7 Preparation of Compound I (Step ii)
[0184] Table 8. Step ii feeding table
[0185]
[0186] The reaction steps are the same as in Example 6:
[0187] 1. Add 1100 mL of dichloromethane and 110 g of compound II (ee value 97.54%) into the reactor at room temperature, stir and cool down.
[0188] 2. Cool down to -5~5℃, add 3-oxetane hydrochloride (41.0g, 1.5 eq) to the reaction bottle, and then drop N,N-diisopropylethylamine (322.4g, 10.0 eq) and 50 wt% 1-propylphosphoric anhydride ethyl acetate solution (476.4g, 1.5 eq) in sequence.
[0189] 3. Control the temperature at -5~5℃ and react for 12~16 hours (take samples until the remaining compound II is ≤0.5%) to obtain compound I.
[0190] Post-processing:
[0191] 1. Control the temperature at -5~5℃ and add 1100 mL of purified water to the reactor.
[0192] 2. Add 15% sodium carbonate aqueous solution to adjust the pH to 9.0-9.7. Heat to 20-30℃ and stir for 2h.
[0193] 3. Filter and then wash the filter cake with about 220 mL of purified water.
[0194] 4. The filter cake was recrystallized with 660 mL of methanol, heated to 55-65 °C and then cooled, filtered, and 101.8 g of compound I was obtained with a purity of 98.94%, an ee value of 97.34%, and a yield of 82.27%.
[0195] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A method for preparing S-configuration oxapropionyl cyclobutylamine, characterized in that: The following steps are involved: (i) In the presence of an esterase, compound III is subjected to an enzymatic hydrolysis reaction to obtain compound II: ; Wherein, the esterase is 503030-V5; The mass ratio of the compound III to the esterase is 1: (0.5-2.5); The temperature of the enzymatic hydrolysis reaction is 30-50°C; The enzymatic hydrolysis reaction time is 10-30 h; The pH range of the enzymatic hydrolysis reaction is 7.0-9.0; (ii) In the presence of a condensation agent, the compound of formula II and 3-oxetane hydrochloride undergo a condensation reaction to obtain compound I, i.e., S-configuration oxapropionyl cyclobutane amine: ; The condensation reagent is T3P or PyBOP; The condensation reaction is carried out in the presence of a base B, and the base B is N,N-diisopropylethylamine; The molar ratio of compound II to base B is 1:(5-15).
2. The method according to claim 1, characterized in that In the step (i), the enzymatic hydrolysis reaction time is 18-22 h.
3. The method according to claim 1, characterized in that In the step (i), the mass ratio of the compound III to the esterase is 1: (1-2).
4. The method according to claim 1, characterized in that In the step (i), the temperature of the enzymatic hydrolysis reaction is 32-45°C.
5. The method according to claim 1, characterized in that The method further comprises the following steps (i-2): recovering the R-configuration compound III in the feed solution in step (i), i.e., compound R-III; and subjecting compound R-III to a racemization reaction in the presence of DBU to obtain compound III; 。 6. The method according to claim 1, wherein: In the step (ii), the molar ratio of the compound of formula II to 3-oxetane hydrochloride is 1: (0.1-4).
7. The method according to claim 1, characterized in that In the step (ii), the condensation reagent is T3P.
8. The method according to claim 1, characterized in that In the step (ii), the condensation reaction is carried out in the presence of a solvent B, and the solvent B is selected from the following group: dichloromethane, acetonitrile or a combination thereof.
9. The method according to claim 1, wherein: In the step (ii), the molar ratio of compound II to base B is 1: (8-12).
10. The method according to claim 1, characterized in that The compound III is prepared by the following steps (i'): Compound V and compound IV undergo a substitution reaction to obtain compound III: 。
